Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors: A pilot study

Sharon M. Castellino, Janet A. Tooze, Lynn Flowers, Debbie F. Hill, Kevin P. McMullen, Edward G. Shaw, Susan K. Parsons

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Neurocognitive deficits are a recognized late effect of curative brain tumor therapy. We evaluated the feasibility, tolerance, and impact of a pilot pharmacologic intervention with the acetylcholinesterase (AChe) inhibitor, donepezil, in pediatric brain tumor (BT) survivors at risk for neurocognitive dysfunction. Procedure: A single institution open-label pilot study was conducted in childhood BT survivors: ≥1 year from cancer treatment; and who received >23.5Gy cranial radiation therapy (RT). Toxicity, adherence and neurocognitive outcomes were evaluated at baseline and serially during 24 weeks of donepezil, and following a 12-week washout period off drug. Results: From a pool of subjects, 13 were successfully contacted and screened, and 11 met all eligibility criteria to initiate donepezil at a median of 4.7 (1.9-11.9) years from RT. Seventy-two percent of patients completed the 24-week drug study visit. Despite transient gastrointestinal toxicity (vomiting and diarrhea) in 30% of patients there was no weight loss on donepezil. Significant improvement in performance was noted at 24 weeks on the Dellis-Kaplan Executive Function (D-KEF) Tower test (P

Original languageEnglish (US)
Pages (from-to)540-547
Number of pages8
JournalPediatric Blood and Cancer
Volume59
Issue number3
DOIs
StatePublished - Sep 2012
Externally publishedYes

Fingerprint

Cholinesterase Inhibitors
Brain Neoplasms
Survivors
Radiotherapy
Executive Function
Pharmaceutical Preparations
Vomiting
Weight Loss
Diarrhea
Pediatrics
donepezil
Therapeutics
Neoplasms

Keywords

  • AChe inhibitor
  • Childhood brain tumor
  • Donepezil
  • Executive function
  • Survivors

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Castellino, S. M., Tooze, J. A., Flowers, L., Hill, D. F., McMullen, K. P., Shaw, E. G., & Parsons, S. K. (2012). Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors: A pilot study. Pediatric Blood and Cancer, 59(3), 540-547. https://doi.org/10.1002/pbc.24078

Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors : A pilot study. / Castellino, Sharon M.; Tooze, Janet A.; Flowers, Lynn; Hill, Debbie F.; McMullen, Kevin P.; Shaw, Edward G.; Parsons, Susan K.

In: Pediatric Blood and Cancer, Vol. 59, No. 3, 09.2012, p. 540-547.

Research output: Contribution to journalArticle

Castellino, SM, Tooze, JA, Flowers, L, Hill, DF, McMullen, KP, Shaw, EG & Parsons, SK 2012, 'Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors: A pilot study', Pediatric Blood and Cancer, vol. 59, no. 3, pp. 540-547. https://doi.org/10.1002/pbc.24078
Castellino, Sharon M. ; Tooze, Janet A. ; Flowers, Lynn ; Hill, Debbie F. ; McMullen, Kevin P. ; Shaw, Edward G. ; Parsons, Susan K. / Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors : A pilot study. In: Pediatric Blood and Cancer. 2012 ; Vol. 59, No. 3. pp. 540-547.
@article{c2ef300e48b5439f88a6990ce40ed12a,
title = "Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors: A pilot study",
abstract = "Background: Neurocognitive deficits are a recognized late effect of curative brain tumor therapy. We evaluated the feasibility, tolerance, and impact of a pilot pharmacologic intervention with the acetylcholinesterase (AChe) inhibitor, donepezil, in pediatric brain tumor (BT) survivors at risk for neurocognitive dysfunction. Procedure: A single institution open-label pilot study was conducted in childhood BT survivors: ≥1 year from cancer treatment; and who received >23.5Gy cranial radiation therapy (RT). Toxicity, adherence and neurocognitive outcomes were evaluated at baseline and serially during 24 weeks of donepezil, and following a 12-week washout period off drug. Results: From a pool of subjects, 13 were successfully contacted and screened, and 11 met all eligibility criteria to initiate donepezil at a median of 4.7 (1.9-11.9) years from RT. Seventy-two percent of patients completed the 24-week drug study visit. Despite transient gastrointestinal toxicity (vomiting and diarrhea) in 30{\%} of patients there was no weight loss on donepezil. Significant improvement in performance was noted at 24 weeks on the Dellis-Kaplan Executive Function (D-KEF) Tower test (P",
keywords = "AChe inhibitor, Childhood brain tumor, Donepezil, Executive function, Survivors",
author = "Castellino, {Sharon M.} and Tooze, {Janet A.} and Lynn Flowers and Hill, {Debbie F.} and McMullen, {Kevin P.} and Shaw, {Edward G.} and Parsons, {Susan K.}",
year = "2012",
month = "9",
doi = "10.1002/pbc.24078",
language = "English (US)",
volume = "59",
pages = "540--547",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors

T2 - A pilot study

AU - Castellino, Sharon M.

AU - Tooze, Janet A.

AU - Flowers, Lynn

AU - Hill, Debbie F.

AU - McMullen, Kevin P.

AU - Shaw, Edward G.

AU - Parsons, Susan K.

PY - 2012/9

Y1 - 2012/9

N2 - Background: Neurocognitive deficits are a recognized late effect of curative brain tumor therapy. We evaluated the feasibility, tolerance, and impact of a pilot pharmacologic intervention with the acetylcholinesterase (AChe) inhibitor, donepezil, in pediatric brain tumor (BT) survivors at risk for neurocognitive dysfunction. Procedure: A single institution open-label pilot study was conducted in childhood BT survivors: ≥1 year from cancer treatment; and who received >23.5Gy cranial radiation therapy (RT). Toxicity, adherence and neurocognitive outcomes were evaluated at baseline and serially during 24 weeks of donepezil, and following a 12-week washout period off drug. Results: From a pool of subjects, 13 were successfully contacted and screened, and 11 met all eligibility criteria to initiate donepezil at a median of 4.7 (1.9-11.9) years from RT. Seventy-two percent of patients completed the 24-week drug study visit. Despite transient gastrointestinal toxicity (vomiting and diarrhea) in 30% of patients there was no weight loss on donepezil. Significant improvement in performance was noted at 24 weeks on the Dellis-Kaplan Executive Function (D-KEF) Tower test (P

AB - Background: Neurocognitive deficits are a recognized late effect of curative brain tumor therapy. We evaluated the feasibility, tolerance, and impact of a pilot pharmacologic intervention with the acetylcholinesterase (AChe) inhibitor, donepezil, in pediatric brain tumor (BT) survivors at risk for neurocognitive dysfunction. Procedure: A single institution open-label pilot study was conducted in childhood BT survivors: ≥1 year from cancer treatment; and who received >23.5Gy cranial radiation therapy (RT). Toxicity, adherence and neurocognitive outcomes were evaluated at baseline and serially during 24 weeks of donepezil, and following a 12-week washout period off drug. Results: From a pool of subjects, 13 were successfully contacted and screened, and 11 met all eligibility criteria to initiate donepezil at a median of 4.7 (1.9-11.9) years from RT. Seventy-two percent of patients completed the 24-week drug study visit. Despite transient gastrointestinal toxicity (vomiting and diarrhea) in 30% of patients there was no weight loss on donepezil. Significant improvement in performance was noted at 24 weeks on the Dellis-Kaplan Executive Function (D-KEF) Tower test (P

KW - AChe inhibitor

KW - Childhood brain tumor

KW - Donepezil

KW - Executive function

KW - Survivors

UR - http://www.scopus.com/inward/record.url?scp=84863858224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863858224&partnerID=8YFLogxK

U2 - 10.1002/pbc.24078

DO - 10.1002/pbc.24078

M3 - Article

C2 - 22238217

AN - SCOPUS:84863858224

VL - 59

SP - 540

EP - 547

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -